Latest news with #Clostridioidesdifficile
Yahoo
06-06-2025
- Business
- Yahoo
Why Summit Therapeutics Inc. (SMMT) Crashed On Wednesday
We recently published a list of . In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other worst-performing stocks on Wednesday. Summit Therapeutics dropped its share prices by 5.14 percent on Wednesday to finish at $19.56 apiece as investors booked early profits following the previous day's gains. Earlier this week, Zacks Equity Research issued a market report on Summit Therapeutics Inc.'s (NASDAQ:SMMT) stock, underscoring a selling pressure that has pushed the company into the oversold territory. Zacks added that the stock could now be due for a turnaround. A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample. Summit Therapeutics Inc. (NASDAQ:SMMT) currently holds a 'buy' recommendation from Zacks, which means that it is in the top 20 percent of more than 4,000 stocks ranked based on trends in earnings estimate revisions and EPS surprises. In recent news, Summit Therapeutics Inc. (NASDAQ:SMMT) announced late last week that it achieved its primary endpoint of progression-free survival for the evaluation of Ivonescimab combined with platinum-doublet chemotherapy. However, investors hungry for more concrete developments appeared unimpressed, as evident in the disposal of its shares. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
04-06-2025
- Business
- Yahoo
Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Tuesday
We recently published a list of . In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other Tuesday's best performers. Summit Therapeutics rebounded on Tuesday, jumping 16.33 percent to finish at $20.62 apiece as investors resorted to bargain-hunting following a selling pressure that pushed the company into the oversold territory. With its stock now down by more than 36 percent in just a month of trading, Zacks Equity Research said that the stock could be due for a turnaround. A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample. Summit Therapeutics Inc. (NASDAQ:SMMT) currently holds a 'buy' recommendation from Zacks, which means that it is in the top 20 percent of more than 4,000 stocks ranked based on trends in earnings estimate revisions and EPS surprises. In recent news, Summit Therapeutics Inc. (NASDAQ:SMMT) announced late last week that it achieved its primary endpoint of progression-free survival for the evaluation of Ivonescimab combined with platinum-doublet chemotherapy. However, investors hungry for more concrete developments appeared unimpressed over the past two trading days, as evident in the disposal of its shares. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Los Angeles Times
22-05-2025
- Health
- Los Angeles Times
Pseudomembranous Colitis (Clostridium Difficile Infection): Risks and Treatment Strategies
Pseudomembranous colitis (PMC) is an antibiotic associated severe inflammatory condition of the colon caused by an overgrowth of Clostridium difficile (C. difficile), a toxin producing bacterium. It's known for forming yellow-white plaques – called pseudomembranes – on the lining of the colon which can be seen during colonoscopy or on histology [1], [6]. Although often linked to antibiotic use, PMC can present with a wide range of severity from mild diarrhea to life threatening colitis. While Clostridioides difficile (formerly Clostridium difficile) is the primary organism behind PMC, it's not the only one. Other pathogens have occasionally been found to cause similar colonic inflammation and pseudomembrane formation [1], [3]. But C. difficile is the most common and clinically relevant. The process starts with antibiotics. These medications while useful for treating bacterial infections can disrupt the balance of normal colonic flora in the gut. This gives C. difficile – often present in small amounts in the intestines – the opportunity to flourish [2], [7], [9]. Spores that were once dormant now find an environment ripe for growth. C. difficile produces two potent toxins, toxin A (TcdA) and toxin B (TcdB). These toxins bind to cells lining the colon, damaging them and setting off a cascade of inflammation. In severe cases the body's immune response and cell damage leads to the hallmark pseudomembranes seen in PMC [5]. Not all antibiotic therapy is created equal, but broad spectrum agents like clindamycin, cephalosporins and fluoroquinolones are often implicated. These drugs wipe out a wide range of gut flora making room for C. difficile to flourish [10]. PMC symptoms often start during or shortly after antibiotics: These symptoms can overlap with other conditions but the timing, especially after antibiotics, is a key clue. PMC doesn't affect everyone the same way. While some people have mild diarrhea others can spiral into severe colitis and complications like: These cases need urgent medical attention. Healthcare providers consider PMC when a patient on antibiotics develops sudden or worsening diarrhea, so rapid diagnosis is key. But diagnosing it isn't always easy. Metronidazole: Metronidazole is used for mild to moderate PMC. It's effective, cheap and oral [1], [8]. But it's being replaced by other treatments due to higher relapse rates and slower symptom resolution. Vancomycin: Oral vancomycin is now the go to for severe or complicated C. difficile infections. It stays in the gut (where it's needed) without being absorbed into the bloodstream so it targets the infection locally. PMC relapses so recurrent Clostridioides difficile infection is common. Some patients may need extended vancomycin tapers, fidaxomicin (a newer antibiotic) or even fecal microbiota transplantation (FMT). FMT involves restoring healthy gut bacteria by transplanting stool from a donor—a treatment that's showing promising results in recurrent Clostridioides difficile infection cases [4]. One of the best ways to prevent PMC is smart antibiotic prescribing. Avoiding unnecessary prescriptions especially broad spectrum antibiotics can help preserve the natural gut microbiome and prevent C. difficile overgrowth. Hospitals and healthcare facilities also have a role to play by enforcing infection control measures such as hand hygiene and isolation protocols to limit the spread of C. difficile spores. Pseudomembranous colitis is more than just a complication of antibiotic use—it's a serious gastrointestinal illness that needs timely diagnosis and treatment. Understanding the underlying disruption of gut microbiota and toxin production is key to managing and preventing this condition. As we learn more about PMC the emphasis remains on prevention through good antibiotic stewardship and early intervention when symptoms occur. [1] Surawicz, C. M., & McFarland, L. V. (1999). Pseudomembranous colitis: causes and cures. Digestion, 60(2), 91–100. [2] Janoir C. (2016). Virulence factors of Clostridium difficile and their role during infection. Anaerobe, 37, 13–24. [3] Tang, D. M., Urrunaga, N. H., & von Rosenvinge, E. C. (2016). Pseudomembranous colitis: Not always Clostridium difficile. Cleveland Clinic journal of medicine, 83(5), 361–366. [4] Surawicz, C. M., & McFarland, L. V. (2000). Pseudomembranous Colitis Caused by C. difficile. Current treatment options in gastroenterology, 3(3), 203–210. [5] Castagliuolo, I., & LaMont, J. T. (1999). Pathophysiology, diagnosis and treatment of Clostridium difficile infection. The Keio journal of medicine, 48(4), 169–174. [6] Farooq, P. D., Urrunaga, N. H., Tang, D. M., & von Rosenvinge, E. C. (2015). Pseudomembranous colitis. Disease-a-month : DM, 61(5), 181–206. [7] Trnka, Y. M., & Lamont, J. T. (1984). Clostridium difficile colitis. Advances in internal medicine, 29, 85–107. [8] Brar, H. S., & Surawicz, C. M. (2000). Pseudomembranous colitis: an update. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 14(1), 51–56. [9] Counihan, T. C., & Roberts, P. L. (1993). Pseudomembranous colitis. The Surgical clinics of North America, 73(5), 1063–1074. [10] Weymann L. H. (1982). Colitis caused by Clostridium difficile: a review. The American journal of medical technology, 48(11), 927–934.
Business Wire
05-05-2025
- Health
- Business Wire
Ferring Presents New Phase 3b Safety and Effectiveness Data for Recurrent
PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals presented initial findings from the investigational Phase 3b multi-center, single-arm CDI-SCOPE study evaluating the safety and effectiveness of REBYOTA ® (fecal microbiota, live – jslm) when administered by colonoscopy. REBYOTA is the first microbiome-based therapy approved for the prevention of recurrent Clostridioides difficile (C. diff) infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for C. diff infection. These data were presented at Digestive Disease Week 2025 (DDW2025) from May 3-6 in San Diego, CA. The single-arm CDI-SCOPE study demonstrated that treatment with REBYOTA administered by colonoscopy was safe. Only 5 treatment-emergent adverse events (TEAEs) – occurring in 9.8% (4/41) of participants – were considered possibly related to REBYOTA, all of which were mild in intensity and related to the gastrointestinal tract. Two participants withdrew consent and did not complete the 8-week follow-up assessment. "Colonoscopies are routinely used by physicians managing patients with recurrent C. difficile infection," said Dr. Paul Feuerstadt, M.D., F.A.C.G., A.G.A.F., Yale School of Medicine and PACT-Gastroenterology Center, a lead investigator of CDI-SCOPE. "The insights gained from this investigative study point to administration via colonoscopy as a promising potential option for physicians to consider for their patients." A second abstract from the CDI-SCOPE study reported the burden of rCDI on health-related quality of life (HRQoL) and any improvements after treatment among 73.2% (30/41) participants. Prior to REBYOTA treatment, the most experienced rCDI symptoms were diarrhea (100%, 30/30), abdominal pain (70.0%, 21/30), and fatigue or weakness (46.7%, 14/30). All participants (100%, 30/30) reported that CDI recurrence impacted their daily living, including disrupting their sleep and forcing them to be near a bathroom at all times. Most participants also said that rCDI affected their social life and relationships (96.7%, 29/30) and their emotional wellbeing (93.3%, 28/30). Following treatment with REBYOTA, 89.7% of participants (26/29) saw an improvement in their symptoms within the first month, and more than half (51.7%, 15/29) felt an improvement within the first week. Symptom severity rating scores (0-10, none to worst) decreased significantly at Week 8 for diarrhea (from 8.9 to 1.3), abdominal pain (from 7.5 to 1.6), and fatigue (from 8.1 to 1.7). 'Recurrent CDI is a life-altering condition that many patients in our CDI-SCOPE trial called 'a literal living nightmare' that makes it impossible to function,' said Raza Ahmed, MD, Senior Director of Medical Affairs, Ferring Pharmaceuticals. 'We are proud that REBYOTA has become an important, therapy for many patients who, for too long, were stuck in an agonizing cycle of CDI recurrence. With the data we are presenting this week at DDW, Ferring is continuing its commitment to supporting patients living with rCDI and their physicians by broadening the breadth of evidence.' A third CDI-SCOPE abstract showed that 90% of the physicians who completed the 41 colonoscopy procedures in the study had a 'positive' or 'very positive' experience across all aspects of administration, including the material preparation time and ease of passage through the colonoscope. One investigator reported their experience as 'somewhat negative' citing difficulty with connecting REBYOTA to the colonoscope. All 39 patients who completed 8-week visits were assessed by the physicians as either having 'much improved' or 'very much improved' on the clinical global impression – improvement scale (CGI-I). Additional Data from PUNCH™ Clinical Program Along with the data from CDI-SCOPE, Ferring also reported two analyses with data from the PUNCH™ clinical trial program. This included: Results from an integrated safety analysis of five clinical trials (n=1192) demonstrating a favorable safety profile with REBYOTA across all trials in the development program, including in participants with inflammatory bowel disease (IBD) and immunocompromising comorbidities. TEAEs were reported in 70.9% of patients who received REBYOTA, most of which were mild or moderate in severity and related to the gastrointestinal tract. Serious TEAEs were reported in 14.3% of patients receiving REBYOTA, most of which were related to rCDI and/or preexisting conditions, with few events (<1%) being considered possibly related to treatment. There was no clustering of serious TEAEs, including in comorbid subgroups. This new exploratory analysis of the PUNCH™ CD3 trial in which improvements in HRQoL were associated with changes in microbiome and metabolome composition. In a previous exploratory analysis, patients who responded to REBYOTA vs. placebo had a healthier gut microbiome composition with an increase in the relative abundance of beneficial gut microbiota (Bacteroidia and Clostridia) and a decrease in other bacteria (Gammaproteobacteria and Bacilli). This new analysis found that the greatest improvements in HRQoL – as measured using the disease-specific C. difficile Quality of Life Survey (Cdiff32), which examines physical, mental and social domains – were associated with the mental health domain, with the largest improvements associated with higher levels of Bacteroidia and Clostridia and lower levels of other bacteria. To learn more about REBYOTA and other information, please visit or About C. diff infection C. diff infection is a serious and potentially deadly infection that impacts people across the globe. The C. diff bacterium causes debilitating symptoms, such as severe diarrhea, fever, stomach tenderness or pain, loss of appetite, nausea and colitis (an inflammation of the colon). 1 C. diff infection can be the start of a vicious cycle of recurrence, causing a significant burden for patients and the healthcare system. 2,3 It has been estimated that up to 35% of C. diff infection cases recur after initial diagnosis and people who have had a recurrence are at significantly higher risk of further infections. 4,5,6,7 After the first recurrence, it has been estimated that up to 65% of patients may develop a subsequent recurrence. 6,7 Antibiotics – the current standard of care for treatment of C. diff infection – treat the disease but can also be a contributing factor to the cycle of recurrence. 1 About REBYOTA REBYOTA is a pre-packaged, single-dose 150 mL microbiota suspension for rectal administration consisting of a liquid mix of up to trillions of live microbes – including Bacteroides. REBYOTA is delivered directly to the gut microbiome and is administered by a healthcare professional in one visit. INDICATION REBYOTA (fecal microbiota, live – jslm) is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection. Limitation of Use REBYOTA is not indicated for the treatment of C. diff infection. IMPORTANT SAFETY INFORMATION You should not receive REBYOTA if you have a history of a severe allergic reaction (e.g., anaphylaxis) to REBYOTA or any of its components. You should report to your doctor any infection you think you may have acquired after administration. REBYOTA may contain food allergens. Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%). REBYOTA has not been studied in patients below 18 years of age. Clinical studies did not determine if adults 65 years of age and older responded differently than younger adults. You are encouraged to report negative side effects of prescription drugs to FDA. Visit or call 1-800-332-1088. Please click to see the full Prescribing Information. About Ferring Pharmaceuticals Ferring Pharmaceuticals is a privately-owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. In the United States, Ferring is a leader in reproductive medicine, and in areas of gastroenterology and orthopaedics. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. The company was founded in 1950 and is headquartered in Saint-Prex, Switzerland. Ferring employs more than 7,000 people worldwide and markets its medicines in over 100 countries. Ferring USA is based in Parsippany, New Jersey, and employs more than 900 employees. For more information, please visit call 1-888-FERRING (1-888-337-7464), or connect with us on LinkedIn, and X. About DDW 2025 Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting from May 3-6, 2025. The meeting showcases more than 5,600 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at References: Centers for Disease Control and Prevention. What is C. diff? 7 Sep. 2022. Available at: Centers for Disease Control and Prevention. 2019 Antibiotic Resistance Threats Report: Clostridioides difficile. 23 Nov. 2021. Available at: Feuerstadt P, et al. Healthcare resource utilization and direct medical costs associated with index and recurrent Clostridioides difficile infection: a real-world data analysis. J Med Econ. 2020;23(6):603-609. Riddle DJ, Dubberke ER. Clostridium difficile infection in the intensive care unit. Infect Dis Clin North Am. 2009;23(3):727-743. Nelson WW, et al. Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis. J Manag Care Spec Pharm. 2021 Jul;27(7):828-838. doi: 10.18553/jmcp.2021.20395. Epub 2021 Mar 11. Kelly, CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect. 2012;18 (Suppl. 6): 21–27. Smits WK, et al. Clostridium difficile
Yahoo
04-05-2025
- Business
- Yahoo
Why Summit Therapeutics Inc. (SMMT) Soared Last Week
We recently published a list of . In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other firms that soared last week. The past trading week saw a more calm, generally optimistic, market environment amid the temporary pause in tit-for-tat tariffs, buoyed further by a flurry of corporate earnings for the first quarter of the year. On a week-on-week basis, the tech-heavy Nasdaq rallied the most, up 3.4 percent, followed by the Dow Jones with 3 percent, and the S&P 500 by 2.9 percent. Beyond the major indices, 10 firms stood out, booking double-digit gains as high as 48 percent, thanks to better-than-expected earnings and outlook. In this article, we name this week's 10 best-performing mid-cap companies and detail the reasons behind their gains. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume. The stocks were chosen based on the highest percentage increase in closing prices on May 2 as against their prices a week earlier, or on April 25. A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample. Summit Therapeutics Inc. (NASDAQ:SMMT) Summit Therapeutics grew its share price by 18.88 percent last week to end Friday at $27.9 versus the $23.47 the week prior, as investor sentiment was boosted by an investment firm's bullish outlook despite the company's disappointing earnings performance in the first quarter of the year. In its market note, Cantor Fitzgerald reaffirmed its Overweight rating on Summit Therapeutics Inc. (NASDAQ:SMMT) stock, thanks to its promising ivonescimab bispecific antibody, which aims to cure cancer. Just recently, Summit Therapeutics Inc. (NASDAQ:SMMT) secured the green light from China to offer ivonescimab as a first-line treatment for PD-L1-positive NSCLC, paving the way for further expansion globally. 'We … appreciate the regulatory authorities for their efficient and diligent review, which enables us to offer this new treatment to patients in China,' the company said. In the first quarter, Summit Therapeutics Inc. (NASDAQ:SMMT) widened its net loss by 44.6 percent to $62.9 million from $43.5 million in the same period last year, as operating expenses picked up by 57.5 percent to $66.8 million from $42.4 million year-on-year. Overall, SMMT ranks 6th on our list of firms that soared last week. While we acknowledge the potential of SMMT as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than SMMT but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
